Our mission is to support ALS (Lou Gehrig’s Disease) research and scientific investigations at the Cecil B. Day Laboratory by raising funds through events, campaigns, foundation grants and numerous other community outreach activities, to aid in finding a cause, treatment and cure for ALS.
Our Non-Profit Setup
Our offices are located in the law firm of Nigro Pettipet and Lucas, courtesy of Directors Jan and Eugene Nigro. Angel Fund President Rich Kennedy and the board members are not paid. As a result, it means we have very low overhead and administrative costs so more money goes to research. We are proud to say that 92% of funds expended goes to research.
- No rent
- No utility bills
- No high paid executives
FDA clears investigational new drug application for ALS gene therapy candidate
Apic Bio, a gene therapy company developing treatment options for patients with rare genetic diseases and co-founded by UMass Medical School’s Robert H. Brown Jr., DPhil, MD, announced that the FDA has cleared its investigational new drug (IND) application for APB-102, a gene therapy candidate designed to treat a common cause of familial amyotrophic lateral sclerosis.